In patients with progressive metastatic (or recurrent) differentiated thyroid carcinoma that either do not take up radioiodine or are unresponsive to continued radioiodine therapy, staging is difficult and treatment options are few. However, in most of these patients uptake of radiolabeled somatostatin analogs is evident on somatostatin-receptor scintigraphy (SRS). Using SRS, patients with suff...

undesired radiation exposure to caregivers is an important problem in radioiodine therapy in thyroid carcinoma patients, especially when patient is non-ambulatory. special precautions are needed to keep the exposure to caregivers low when higher dose of radioiodine is necessary. here we present a case-report of a 74-year old male patient with papillary thyroid carcinoma with local invasion and ...

The management of hyperthyroidism in the pregnant woman has been the topic of several recent reviews (1–6) and case series (7–8). These papers have discussed maternal-fetal thyroid relationships, the epidemiology of maternal hyperthyroidism, causes of gestational thyrotoxicosis, the clinical and laboratory diagnosis of hyperthyroidism in pregnancy, therapy with ATDs, surgery, b adrenergic block...

MV-NIS is an engineered measles virus that is selectively destructive to myeloma plasma cells and can be monitored by noninvasive radioiodine imaging of NIS gene expression. Two measles-seronegative patients with relapsing drug-refractory myeloma and multiple glucose-avid plasmacytomas were treated by intravenous infusion of 10(11) TCID50 (50% tissue culture infectious dose) infectious units of...

Use of radioactive iodine is an essential adjuvant treatment strategy after thyroidectomy in patients with differentiated thyroid carcinoma. Although generally safe, radioiodine therapy has some potential side effects, classified as early and late complications, which we have reviewed in this paper. Early complications include gastrointestinal symptoms, radiation thyroiditis, sialadenitis/xeros...

Since all isotopes of any element have identical chemical behaviour, the radioactive isotopes of iodine are metabolised in the same way as normal iodine, and become highly concentrated in normal or over-active thyroid tissue and, in some circumstances , in thyroid cancer tissue. It may consequently be possible to destroy part or all of such tissues by the effects of the intense local beta radia...

Presently, there is very little data on the impact of nicotine and other components of tobacco smoking on the outcome of radioiodine therapy (RIT) in Graves’ disease (GD). Thus, this study was aimed to analyze a possible impact of cigarette smoking on the effect of radioiodine therapy in the patients with Graves’ disease. The study included 31 patients (16 smokers and 15 non-smokers) with GD, a...

Respiratory distress accompanied by stridor is an uncommon complication of 131I radioiodine therapy for differentiated thyroid cancer that occurs within 48 hours of treatment. This report presents three cases with papillary thyroid carcinoma in which 131I therapy caused this acute complication. One of them had no apparent risk for this complication such as the existence of remnant thyroid tissu...

OBJECTIVE To evaluate 131I therapy in elderly patients with subclinical hyperthyroidism (SCH) due to nodular disease and who did not receive antithyroid drugs (ATDs), and the effect of the treatment on bone metabolism. SUBJECTS AND METHODS Thirty-six patients with TSH ≤ 0.1 mIU/L and non-voluminous goiter (< 60 cm³) were studied. Bone mineral density (BMD) was assessed in 17 women with osteop...

yperthyroidism is a common endocrine disorder. A recent national survey found a prevalence of 0.5% in the general US population. The most common cause of hyperthyroidism is Graves’ disease, which accounts for 80% to 90% of cases. Three treatment options currently are available for patients with Graves’ disease: radioiodine therapy, antithyroid drugs, and thyroidectomy. The clinician should choo...